Upstream Bio director granted 17,096 stock options
Upstream Bio, Inc. director Daniella Beckman received a grant of stock options covering 17,096 shares of common stock.
Rhea-AI Filing Summary
Upstream Bio, Inc. director Daniella Beckman received a grant of stock options covering 17,096 shares of common stock. The options have an exercise price of $6.69 per share and expire on June 8, 2036. Following this grant, she holds 17,096 derivative securities directly.
These options will vest in full on the earlier of June 9, 2027 or the date of the company’s next Annual Meeting of Stockholders, provided she continues to serve through the vesting date. This filing reflects a compensation-related award rather than an open-market transaction.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 17,096 shares
Grant/Award
1 txn
Insider
Beckman Daniella
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 17,096 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 17,096 contracts (Direct)
Footnotes (1)
- F1. The shares underlying this option shall vest in full upon the earlier of (i) June 9, 2027 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date.
Key Figures
Options granted: 17,096 options
Exercise price: $6.69 per share
Expiration date: June 8, 2036
+2 more
5 metrics
Options granted
17,096 options
Grant of stock options to director on June 9, 2026
Exercise price
$6.69 per share
Strike price of stock option grant
Expiration date
June 8, 2036
Option term end date for the grant
Underlying shares
17,096 shares
Common stock underlying the options
Post-transaction holdings
17,096 derivative securities
Options held directly after the grant
Key Terms
Stock Option (Right to Buy), exercise price, expiration date, Annual Meeting of Stockholders
4 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price: 6.6900"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: 2036-06-08T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
Annual Meeting of Stockholders financial
"earlier of June 9, 2027 and the date of the next Annual Meeting of Stockholders"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Upstream Bio (UPB) report for Daniella Beckman?
Upstream Bio reported that director Daniella Beckman received a grant of stock options for 17,096 shares. This is a compensation-related award, not an open-market trade, and gives her the right to buy common stock at a fixed exercise price.
How many Upstream Bio (UPB) stock options were granted to Daniella Beckman?
Daniella Beckman was granted stock options covering 17,096 underlying shares of Upstream Bio common stock. All 17,096 derivative securities are shown as held directly after the transaction, reflecting her entire option position from this grant in the filing.
What is the exercise price and expiration date of the Upstream Bio (UPB) options?
The stock options granted to Daniella Beckman have an exercise price of $6.69 per share and expire on June 8, 2036. She can choose to exercise these options any time after they vest and before the expiration date, subject to plan terms.
When do Daniella Beckman’s Upstream Bio (UPB) stock options vest?
The options will vest in full on the earlier of June 9, 2027 or the date of Upstream Bio’s next Annual Meeting of Stockholders. Vesting is contingent on her continued service with the company through that vesting date, according to the footnote disclosure.
Is the Upstream Bio (UPB) Form 4 transaction a stock purchase or sale?
The Form 4 shows an option grant acquisition, not a stock purchase or sale. Code A indicates a grant or award, so Beckman received options as compensation rather than buying in the market or selling existing shares of Upstream Bio stock.
How significant is this Upstream Bio (UPB) insider option grant for investors?
This Form 4 reflects a routine director compensation grant of 17,096 options. It does not involve cash trades in the open market and is a standard equity incentive, so its direct market impact is typically limited compared with large insider purchases or sales.
AI-generated analysis. How Rhea-AI works. Not financial advice.
